Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
• Helus Pharma has completed enrollment ahead of schedule for the Phase 3 APPROACH study, which evaluates HLP003 as an adjunctive treatment for Major Depressive Disorder. • The company is continuing enrollment for EMBRACE, a second pivotal study within the Phase 3 PARADIGM Program, while rolling participants into the EXTEND study for long-term safety data. • This milestone is significant as HLP003 has previously been granted Breakthrough Therapy designation, signaling its potential to provide substantial improvement over existing therapies.
investingnews.com





